Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a challenge to antibiotic treatment, but eravacycline shows promise as a potential treatment option; however, its resistance mechanisms remain unclear.
A study of 287 CRAB isolates from China identified that approximately 17% exhibited heteroresistance to eravacycline, mainly among strains that also produced the OXA-23 carbapenemase, with a significant correlation to higher expression levels of certain resistance genes.
The study found that the presence of efflux pump inhibitors could reduce eravacycline resistance, indicating potential avenues for improving treatment strategies against CRAB infections. *